Innovent Biologics grabs $100 mln Series C
Chinese biopharmaceutical firm Innovent Biologics has closed $100 million in Series C funding. Legend Capital led the round with participation from other backers that included Temasek, Fidelity Biosciences, Fidelity Growth Partners Asia, Lilly Asia Ventures and Frontline Bioventures.
26 January 2015•3 mins read
